Transcatheter Mitral Valve Repair & Replacement Market

Executive Summary

Transcatheter Mitral Valve Repair & Replacement Market was valued at US $951.13 million in 2021 and is projected to grow at 14.44% CAGR over the forecast period to reach US $2,136.76 million by 2027. Transcatheter Mitral Valve Repair & Replacement Market represented US $224.91 million opportunity over 2019-2021 and estimated to create US $1,185.63 million opportunity in 2027 over 2021.

Transcatheter Mitral Valve Repair & Replacement from Consainsights analyses the Transcatheter Mitral Valve Repair & Replacement Market in the Life Sciences industry over the forecast period to 2027.

Transcatheter Mitral Valve Repair & Replacement research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Transcatheter Mitral Valve Repair & Replacement segmentation includes Indication, Region and Geography.

Based on the Indication, the Transcatheter Mitral Valve Repair & Replacement analysis covers MITRAL VALVE STENOSIS, MITRAL VALVE PROLAPSE, MITRAL VALVE REGURGITATION.

In Indication segment, MITRAL VALVE STENOSIS segment has highest cagr growth of 12.74%.

Based on the Region, the Transcatheter Mitral Valve Repair & Replacement analysis covers NORTH AMERICA, EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, NORTH AMERICA segment has highest cagr growth of 12.74%.

Based on the region, the Transcatheter Mitral Valve Repair & Replacement analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ABBOTT LABORATORIES, BIOTRONIK SE & CO. KG, COLIBRI HEART VALVE, LLC., EDWARDS LIFE SCIENCE CORPORATION, HLT, INC., LIVANOVA PLC, MEDTRONIC PLC, NEOVASC INC., NEOCHORD INC., CORAMAZE TECHNOLOGIES GMBH. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Indication

Introduction

In 2021, MITRAL VALVE STENOSIS segment has the highest revenue of US $524.56 million and is expected to grow at CAGR of 12.74% by 2027 MITRAL VALVE STENOSIS segment has highest cagr growth of 12.74%.

MITRAL VALVE STENOSIS

MITRAL VALVE STENOSIS segment was valued at US $400.52 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $1,178.45 million by 2027. MITRAL VALVE STENOSIS segment represented US $124.04 million opportunity over 2019-2021 and estimated to create US $653.89 million opportunity in 2027 over 2021.

MITRAL VALVE PROLAPSE

MITRAL VALVE PROLAPSE segment was valued at US $192.83 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $567.36 million by 2027. MITRAL VALVE PROLAPSE segment represented US $59.72 million opportunity over 2019-2021 and estimated to create US $314.81 million opportunity in 2027 over 2021.

MITRAL VALVE REGURGITATION

MITRAL VALVE REGURGITATION segment was valued at US $132.87 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $390.95 million by 2027. MITRAL VALVE REGURGITATION segment represented US $41.15 million opportunity over 2019-2021 and estimated to create US $216.93 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, NORTH AMERICA segment has the highest revenue of US $395.10 million and is expected to grow at CAGR of 12.74% by 2027 NORTH AMERICA segment has highest cagr growth of 12.74%.

NORTH AMERICA

NORTH AMERICA segment was valued at US $301.67 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $887.60 million by 2027. NORTH AMERICA segment represented US $93.43 million opportunity over 2019-2021 and estimated to create US $492.51 million opportunity in 2027 over 2021.

EUROPE

EUROPE segment was valued at US $228.46 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $672.21 million by 2027. EUROPE segment represented US $70.76 million opportunity over 2019-2021 and estimated to create US $372.99 million opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $158.64 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $466.75 million by 2027. ASIA-PACIFIC segment represented US $49.13 million opportunity over 2019-2021 and estimated to create US $258.99 million opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $37.45 million in 2019 and is projected to grow at 12.74% CAGR over the forecast period to reach US $110.19 million by 2027. LAMEA segment represented US $11.60 million opportunity over 2019-2021 and estimated to create US $61.14 million opportunity in 2027 over 2021.